Demographic and clinical characteristics of the safety population
| Group; mean ± SD* | |||
|---|---|---|---|
| Characteristic | Placebo, n = 186 | Levomilnacipran ER, 40 mg/day, n = 188 | Levomilnacipran ER, 80 mg/day, n = 188 |
| Age, yr | 42.3 ± 13.2 | 42.9 ± 13.4 | 43.1 ± 12.8 |
| Sex, female, % | 62.4 | 62.2 | 66.0 |
| Race, white, % | 72.6 | 75.5 | 73.9 |
| Weight, kg | 81.6 ± 17.8 | 81.4 ± 17.1 | 81.7 ± 17.6 |
| Body mass index | 28.7 ± 5.2 | 28.3 ± 5.2 | 28.7 ± 5.7 |
| MDD history | |||
| Age at onset, yr | 29.2 ± 13.4 | 30.1 ± 12.5 | 28.4 ± 13.5 |
| No. depressive episodes | 3.5 ± 2.4 | 3.5 ± 2.0 | 3.5 ± 2.1 |
| Duration of current episode, mo | 6.6 ± 3.2 | 6.6 ± 3.1 | 6.3 ± 3.0 |
| Duration of MDD, yr | 13.1 ± 10.1 | 12.8 ± 10.2 | 14.7 ± 11.2 |
| Use of previous antidepressant, no. (%) | 106 (57.0) | 110 (58.5) | 108 (57.4) |
| Nonresponse to ≥ 1 previous antidepressant, no. (%) | 40 (21.5) | 38 (20.2) | 47 (25.0) |
| Treatment duration, d | 50.8 ± 12.8 | 49.0 ± 15.7 | 48.3 ± 16.1 |
| Patient-years† | 25.9 | 25.2 | 24.9 |